HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

#MeToo movement in medicine: ‘Community of allies’ required to end culture of sexual harassment


Getting the word out: Effective communication key to ensuring informed choices

John Sweetenham, MD


Precision immunotherapy: Giving the right drug to the right patient at the right time

Razelle Kurzrock, MD; Vivek Subbiah, MD

Meeting News

Addition of palbociclib to fulvestrant extends OS among certain women with advanced breast cancer

Alpelisib prolongs PFS for PIK3CA-mutant advanced breast cancer

Olaparib confers ‘unprecedented’ PFS benefit in ovarian cancer

Liquid biopsy test confirms remission in HPV-associated oral cancer

Stereotactic ablative radiotherapy for renal cell carcinoma safe in patients with solitary kidney

Shorter trastuzumab course may be viable for some women with early HER2-positive breast cancer

Use of targeted treatments for advanced cancer increasing in community setting

Vandetanib shows promise for advanced thyroid cancer

Women more likely to experience key side effects from chemotherapy for esophagogastric cancer

SD-101 plus pembrolizumab induces response in recurrent, metastatic head and neck cancer

Sarcoma treatments evolve as understanding of disease biology improves

Triple combination appears safe, effective for advanced BRAF V600-mutant melanoma

Nivolumab benefit in advanced head and neck cancer maintained regardless of age

Immune-related adverse events manageable with vigilance, appropriate treatment

Second-line therapy for myelofibrosis remains ‘active area of research’

Cognitive computing platform may help oncologists deliver subspecialist-level care

Ribociclib-fulvestrant combination extends PFS for certain postmenopausal women with breast cancer

More research needed to realize true benefit of PARP inhibitors in breast cancer

In the Journals Plus

Denosumab effective in transfusion-dependent thalassemia-induced osteoporosis

Dabrafenib-trametinib combination shows durable RFS benefit in BRAF V600-mutant melanoma

Variant reclassifications ‘common’ after hereditary cancer genetic testing

Black women more likely to skip breast cancer treatment

FDA News

FDA announces new steps to curb youth tobacco use

FDA approves pembrolizumab for hepatocellular carcinoma, lung cancer indications

FDA grants priority review to Tecentriq combination for advanced triple-negative breast cancer

FDA approves Udenyca, biosimilar to pegfilgrastim, for patients receiving myelosuppressive chemotherapy

FDA grants priority review to Lynparza for maintenance therapy of BRCA-positive ovarian cancer

FDA approves triplet regimen for relapsed, refractory myeloma

FDA grants fast track designation to selinexor for relapsed or refractory diffuse large B-cell lymphoma

FDA grants priority review to Jakafi for acute graft-versus-host disease

FDA grants priority review to Lonsurf for advanced gastric adenocarcinoma

FDA approves Khapzory for injection

Arti Hurria, MD, remembered as ‘true giant’ in oncology, tireless advocate for patients

Five individuals receive American Cancer Society Medal of Honor

Four elected to ASH executive committee

Rutgers Cancer Institute section chief receives distinguished service award

Yale Cancer Center names neuro-oncology chief